Epkinly is a novel drug approved by fda (on last May 19) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma(DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. The IgG1 antibody Epcoritamab is manufactured in CHOcells.
👉 CHO cells play a fundamental role in the manufacturing of many biological products and are widely used also in research and development.
Magellan Biologics’ CHO4Tx® is a whole system (CHO 4Tx® cell line + CHO 4Tx® media + CHO 4Tx® protocol) dedicated to Transient Protein Expression in CHO cells. By making this process easy, efficient and cost effective in particular for high-throughput screening Magellan Biologics & Consulting supports research and development projects whole around the world.
